Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Chubb
Colorcon
Cerilliant
Moodys
Citi
Harvard Business School
Merck
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,153,635

« Back to Dashboard

Claims for Patent: 6,153,635

Title: Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
Abstract:A method for treating vulvovaginal candidiasis including the steps of: (a) administering a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier intra-vaginally; and (b) applying miconazole nitrate in a pharmaceutically acceptable carrier to the vulva. Also a kit for the treatment of vulvovaginal candidiasis including: (a) a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier and in a form adapted to be administered intra-vaginally; and (b) an amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva.
Inventor(s): Upmalis; David H. (Newtown, PA)
Assignee:
Application Number:09/197,019
Patent Claims: 1. A method for treating vulvovaginal candidiasis consisting essentially of the steps of:

(a) administering a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier intra-vaginally; and

(b) applying topically miconazole nitrate in a pharmaceutically acceptable carrier to the vulva.

2. The method of claim 1, wherein the single dose of miconazole nitrate administered intra-vaginally comprises about 400 to about 2000 mg of miconazole nitrate.

3. The method of claim 1, wherein the single dose of miconazole nitrate administered intra-vaginally comprises about 600 to about 1200 mg of miconazole nitrate.

4. The method of claim 1, wherein the single dose of miconazole nitrate administered intra-vaginally comprises 2.5 g of 16% miconazole nitrate cream, 5 g of 8% miconazole nitrate cream, 5 g 12% miconazole nitrate cream or 5 g 16% miconazole nitrate cream.

5. The method of claim 1, wherein step (b) is performed 1-2 times per day.

6. The method of claim 1, wherein step (b) is performed 1-2 times per day for about 7 days.

7. The method of claim 3, wherein step (b) is performed 1-2 times per day for about 7 days.

8. A kit for the treatment of vulvovaginal candidiasis consisting essentially of:

(a) a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier and in a form adapted to be administered intra-vaginally; and

(b) an amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva.

9. The kit of claim 8, wherein the single dose of miconazole nitrate adapted to be administered intra-vaginally comprises about 400 to about 2000 mg of miconazole nitrate.

10. The kit of claim 8, wherein the single dose of miconazole nitrate adapted to be administered intra-vaginally comprises about 600 to about 1200 mg of miconazole nitrate.

11. The kit of claim 8, wherein the single dose of miconazole nitrate adapted to be administered intra-vaginally comprises 2.5 g of 16% miconazole nitrate cream, 5 g of 8% miconazole nitrate cream, 5 g 12% miconazole nitrate cream or 5 g 16% miconazole nitrate cream.

12. The kit of claim 8, wherein the amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva is a sufficient amount to be applied 1-2 times per day for about 7 days.

13. The kit of claim 10, wherein the amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva is a sufficient amount to be applied 1-2 times per day for about 7 days.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Merck
Mallinckrodt
Chubb
Federal Trade Commission
Citi
Fish and Richardson
McKesson
Deloitte
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot